Gina Iacoboni, PA
Surgical Oncology · Pittsburgh, PANPI 1164017307
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $587 of the $685 with a category attached, or 85.7%. It is spread thinly across 12 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for surgical oncology clinicians in PA, where the typical reported total is $868.
Across 42 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$126
- AbbVie$125
- AstraZeneca$80
- Novo Nordisk$68
- Amarin Pharma, Inc.$60
- Astellas Pharma US Inc$51
- plus $176 from 6 others
What the payments were for
- Food & beverage$58786%
- Education$9814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 3 | $126 |
| AbbVie | 11 | $125 |
| AstraZeneca | 6 | $80 |
| Novo Nordisk | 5 | $68 |
| Amarin Pharma, Inc. | 3 | $60 |
| Astellas Pharma US Inc | 3 | $51 |
| Boehringer Ingelheim | 3 | $50 |
| Dexcom, Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| GSK | 1 | $12 |
How this compares
$685 in reported general payments places this provider in the 45th percentile of 78 surgical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 28 | $4,493 |
| Pantoprazole Sodium | 12 | $79 |
| Oxycodone Hcl | 29 | $48 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Pittsburgh
- Matthew HoltzmanPittsburgh$11K
- Amer ZureikatPittsburgh$9K
- Suzanne SchiffmanPittsburgh$7K
- Norman WolmarkPittsburgh$7K
- Quratulain SabihPittsburgh$5K
- Marc BrozovichPittsburgh$5K
- Victoria KimPittsburgh$3K
- David BartlettPittsburgh$2K
- Emilia DiegoPittsburgh$1K
- Andrew WatsonPittsburgh$868
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.